0.18%
4.31%
0.86%
-7.11%
-10.43%
-15.37%
-22.06%
AI Spotlight on GSK
Company Description
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology.
It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories.The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews.It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc.
and Vir Biotechnology, Inc.The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Market Data
| Last Price | 1404.5 |
| Change Percentage | 0.18% |
| Open | 1404 |
| Previous Close | 1402 |
| Market Cap ( Millions) | 57311 |
| Volume | 3074889 |
| Year High | 1823.5 |
| Year Low | 1282.5 |
| M A 50 | 1345.51 |
| M A 200 | 1516.28 |
Financial Ratios
| FCF Yield | 7.53% |
| Dividend Yield | 4.34% |
| ROE | 18.08% |
| Debt / Equity | 114.64% |
| Net Debt / EBIDTA | 142.16% |
| Price To Book | 4.09 |
| Price Earnings Ratio | 22.83 |
| Price To FCF | 13.28 |
| Price To sales | 1.83 |
| EV / EBITDA | 7.76 |
News
- Jan -29 - GSK announces EMA accepted for review the MAA for depemokimab
- Jan -29 - The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
- Jan -27 - GSK and Oxford researchers to create cancer vaccine to stop disease developing
- Jan -21 - Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer
- Jan -20 - Is GSK plc (GSK) an Undervalued Defensive Stock for 2025?
- Jan -18 - Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
- Jan -17 - Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
- Jan -16 - Is GSK plc (GSK) One of the Cheapest Stocks with Biggest Upside Potential?
- Jan -13 - Healthcare M&A poised for a rebound in 2025
- Jan -13 - GSK CEO on US Expansion, M&A, Drug Pipeline, Trump
- Jan -13 - Moderna cuts sales forecast on weaker vaccine demand
- Jan -13 - GSK buys US-based rare cancer treatment developer for up to £1bn
- Jan -13 - GSK Enters Agreement to Acquire IDRx, Inc.
- Jan -06 - Why Is GSK plc (NYSE:GSK) Among the Best FTSE Dividend Stocks to Buy Now?
- Jan -04 - GSK’s Nucala Gains Approval in China for CRSwNP
- Jan -03 - GSK's Sinus Disease Drug Secures Approval In China
- Dec -17 - GSK announces CHMP of the EMA recommended expanding approval of Jemperli
- Dec -17 - GSK announces FDA granted BTD for Jemperli
- Dec -17 - GSK’s lung cancer therapy gains EMA PRIME designation
- Dec -10 - GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Commercial Operations
Expected Growth : 4 %
What the company do ?
Commercial Operations at GSK plc oversees the sales, marketing, and distribution of pharmaceutical products, ensuring their availability to patients and healthcare professionals.
Why we expect these perspectives ?
GSK plc's Commercial Operations segment growth is driven by increasing demand for vaccines and specialty medicines, successful product launches, and strategic partnerships. Additionally, expansion into emerging markets, improved sales force effectiveness, and enhanced digital capabilities contribute to the 4% growth rate.
Gsk Plc Products
| Product Range | What is it ? |
|---|---|
| Advair | A medication used to treat asthma and chronic obstructive pulmonary disease (COPD) |
| HIV Medicines | A range of medications used to treat HIV infection |
| Sensodyne | A range of toothpastes and mouthwashes designed to relieve sensitivity |
| Panadol | A range of pain relief medications |
| Nicorette | A range of nicotine replacement therapy (NRT) products |
| Horlicks | A range of malted milk drinks |
| Theraflu | A range of over-the-counter medications used to treat cold and flu symptoms |
| Vaccines | A range of vaccines used to prevent infectious diseases |
GSK plc's Porter Forces
Threat Of Substitutes
GSK plc has a moderate threat of substitutes due to the presence of alternative treatments and products in the pharmaceutical industry.
Bargaining Power Of Customers
GSK plc has a low bargaining power of customers due to the fragmented nature of the pharmaceutical market and the lack of concentration among buyers.
Bargaining Power Of Suppliers
GSK plc has a moderate bargaining power of suppliers due to the presence of multiple suppliers in the pharmaceutical industry, but also due to the high switching costs associated with changing suppliers.
Threat Of New Entrants
GSK plc has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including high research and development costs and stringent regulatory requirements.
Intensity Of Rivalry
GSK plc operates in a highly competitive pharmaceutical industry, with intense rivalry among established players, which drives innovation and pricing pressures.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 55.97% |
| Debt Cost | 4.91% |
| Equity Weight | 44.03% |
| Equity Cost | 5.30% |
| WACC | 5.08% |
| Leverage | 127.12% |
GSK plc : Quality Control
GSK plc passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| AZN.L | AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, … |
| SAN.PA | Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, … |
| ROG.SW | Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products … |
| BAYN.DE | Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for … |
| NOVN.SW | Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Novartis
A-Score
1-Year Total Return ->
🥈
Sanofi
A-Score
1-Year Total Return ->
🥉
Roche
A-Score
1-Year Total Return ->
4
GSK
A-Score
1-Year Total Return ->
5
AstraZeneca
A-Score
1-Year Total Return ->
6
